{
  "ticker": "INBX",
  "company_name": "Inhibrx Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04198766",
      "title": "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma",
      "start_date": "2019-12-10",
      "completion_date": "2027-05-12",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    },
    {
      "nct_id": "NCT03715933",
      "title": "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Ewing Sarcoma",
      "start_date": "2018-10-08",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    },
    {
      "nct_id": "NCT03815396",
      "title": "Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Alpha-1 Antitrypsin Deficiency, AATD",
      "start_date": "2019-07-19",
      "completion_date": "2022-08-18",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    },
    {
      "nct_id": "NCT06353997",
      "title": "Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Triple Negative Breast Cancer",
      "start_date": "2024-09-05",
      "completion_date": "2029-06",
      "enrollment": 0,
      "sponsor": "Providence Health & Services"
    },
    {
      "nct_id": "NCT06295731",
      "title": "INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS\u226520 HNSCC",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "start_date": "2024-05-14",
      "completion_date": "2029-05",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    },
    {
      "nct_id": "NCT04950075",
      "title": "Study of INBRX-109 in Conventional Chondrosarcoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Conventional Chondrosarcoma",
      "start_date": "2021-09-23",
      "completion_date": "2026-12",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    },
    {
      "nct_id": "NCT03809624",
      "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma",
      "start_date": "2019-01-30",
      "completion_date": "2024-10-03",
      "enrollment": 0,
      "sponsor": "Inhibrx Biosciences, Inc"
    }
  ],
  "summary": {
    "total_trials": 7,
    "by_phase": {
      "PHASE1, PHASE2": 1,
      "PHASE1": 3,
      "PHASE2": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "ACTIVE_NOT_RECRUITING": 2,
      "RECRUITING": 3,
      "COMPLETED": 1,
      "TERMINATED": 1
    },
    "active_trials": 5,
    "completed_trials": 1,
    "conditions": [
      "Alpha-1 Antitrypsin Deficiency, AATD",
      "Conventional Chondrosarcoma",
      "Ewing Sarcoma",
      "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "Metastatic Solid Tumors, Non-small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Gastric Adenocarcinoma, Renal Cell Carcinoma, Esophageal Adenocarcinoma, Nasopharyngeal Carcinoma, Oropharyngeal Carcinoma",
      "Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma",
      "Triple Negative Breast Cancer"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:04.059583",
    "search_query": "Inhibrx Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Inhibrx+Biosciences,+Inc."
  }
}